Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Cells|July 6, 2023
Involvement of Substance P (SP) and Its Related NK1 Receptor in Primary Sjögren's Syndrome (pSS) PathogenesisPamela Rosso, Elena Fico, Serena Colafrancesco, et al.
Reumatismo|November 5, 2024
PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitorsCristina Garufi, Silvia Mancuso, Fulvia Ceccarelli, et al.
Virchows Archiv : an International Journal of Pathology|November 18, 2017
Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsyBruna Cerbelli, Annalinda Pisano, Serena Colafrancesco, et al.
Journal of Immunology Research|January 3, 2022
VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian PopulationAndrea Latini, Giada De Benedittis, Carlo Perricone, et al.
Clinical and Experimental Rheumatology|October 23, 2020
Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsyGiacomo Cafaro, Carlo Perricone, Chiara Baldini, et al.
The Journal of Rheumatology|May 17, 2017
Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid TissueLuca Quartuccio, Chiara Baldini, Roberta Priori, et al.
Arthritis Research & Therapy|December 13, 2019
Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian expertsSerena Colafrancesco, Maria Manara, Alessandra Bortoluzzi, et al.
Arthritis Research & Therapy|January 11, 2020
Correction to: Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian expertsSerena Colafrancesco, Maria Manara, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology|August 2, 2022
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational studyRossana Scrivo, Chiara Castellani, Silvia Mancuso, et al.
Clinical Rheumatology|August 7, 2012
Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agentsRossana Scrivo, Ilaria Sauzullo, Fabio Mengoni, et al.
Pageof 13